INTS · XBRL financial data
Intensity Therapeutics financial statements, every fiscal year
The same tables from 3 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (INTS's year ends in late December)
| In thousands of dollars | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|
| Research and development | 4,786 | 10,496 | 6,785 |
| General and administrative | 3,533 | 6,089 | 5,187 |
| Total operating expenses | 8,319 | 16,585 | 11,972 |
| Operating income (loss) | (8,319) | (16,585) | (11,972) |
| Interest income | 324 | 314 | 180 |
| Interest expense | 305 | 0 | — |
| Other income (expense) | — | 3 | 186 |
| Income tax expense (benefit) | 0 | 0 | 0 |
| Net income (loss) | (10,538) | (16,268) | (11,606) |
| Earnings per share, basic‡ USD per share | (34.50) | (29.25) | (214.00) |
| Earnings per share, diluted‡ USD per share | (34.50) | (29.25) | (214.00) |
| Weighted average shares, basic‡ thousands of shares | 345 | 556 | 54 |
| Weighted average shares, diluted‡ thousands of shares | 345 | 556 | 54 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (February 2026); filings made before it reported them unadjusted.
- † Share count changed about 1/6 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (INTS's year ends in late December)
| In thousands of dollars | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|
| Cash and cash equivalents | 8,556 | 2,590 | 11,921 |
| Prepaid and other current assets | 688 | 773 | 788 |
| Total current assets | 15,464 | 3,363 | 12,709 |
| Right-of-use asset | 147 | 122 | 96 |
| Total assets | 17,295 | 4,783 | 14,101 |
| Accounts payable | 3,048 | 1,219 | 583 |
| Accrued liabilities | 891 | 508 | 1,532 |
| Total current liabilities | 3,959 | 1,755 | 2,146 |
| Lease liability, non-current | 138 | 110 | 79 |
| Total liabilities | 4,133 | 1,865 | 2,225 |
| Accumulated deficit | (50,515) | (66,783) | (78,389) |
| Total stockholders' equity | 13,162 | 2,918 | 11,876 |
| Total liabilities and equity | 17,295 | 4,783 | 14,101 |
| Common shares outstanding (cover page)‡ thousands of shares | 548 | 607 | 102 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (February 2026); filings made before it reported them unadjusted.
- † Share count changed about 1/6 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (INTS's year ends in late December)
| In thousands of dollars | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|
| Net income (loss) | (10,538) | (16,268) | (11,606) |
| Stock-based compensation | 1,398 | 3,073 | 2,000 |
| Net cash from operating activities | (7,205) | (15,220) | (9,233) |
| Net cash from investing activities | (6,023) | 6,354 | 0 |
| Proceeds from long-term debt | 230 | 0 | — |
| Net cash from financing activities | 20,472 | 2,900 | 18,564 |
| Net change in cash | 7,244 | (5,966) | 9,331 |
- † Share count changed about 1/6 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
- A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Intensity Therapeutics | 9,529 | not reported | (2,340)* | 3.3M | 4.1 quarters | 10-QJun 30, 2026 |
| Genprex | 15,154 | not reported | (5,139)* | 819,709 | 2.9 quarters | 10-QJun 30, 2026 |
| Bolt Biotherapeutics | 12,860 | 5 | (6,540)* | 1.9M | 2.7 quarters | 10-QJun 30, 2026 |
| VivoSim Labs | 1,670 | 18 | (3,213) | 14.9M | 0.5 quarters | 10-QJun 30, 2026 |
| Orgenesis | 78 | 301* | (2,098)* | 9.8M | 0.0 quarters | 10-KDec 31, 2024 |
| Zeo ScientifiX | 2,265 | not reported | not reported | 7.8M | — | 10-KTJun 30, 2026 |
| Sunshine Biopharma | 13,748 | 9,264 | (918)* | 3.9M | 15.0 quarters | 10-QJun 30, 2026 |
| Neuphoria Therapeutics | 19,866 | year only | 1,214* | 5.4M | — | 10-KJun 30, 2026 |
| CV Sciences | 266 | 2,985 | 20* | 225.8M | — | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.